Proteolysis targeting chimera (PROTAC) technology, the recruitment of E3 ubiquitin ligases
to induce the degradation of a protein target, is rapidly impacting chemical biology, as well …

Abstract Proteolysis Targeting Chimeras (PROTACs) represent a promising therapeutic
modality to address undruggable and resistant issues in drug discovery. However, potential …

Degradation of targeted proteins using proteolysis targeting chimeras (PROTACs) has
gained momentum. A PROTAC is a bifunctional molecule that consists of three parts: a …

The non-enzymatic functions of target proteins play key roles in the regulation of various cell
signaling pathways and are closely related to numerous human diseases. However …

Despite dramatic advances in drug discovery over the decades, effective therapeutic
strategies for cancers treatment are still in urgent demands. PROteolysis TArgeting Chimera …

Targeting protein degradation with Proteolysis-Targeting Chimeras (PROTACs) is an area of
great current interest in drug discovery. Nevertheless, although the high effectiveness of …

Targeted degradation approaches such as proteolysis targeting chimeras (PROTACs) offer
new ways to address disease through tackling challenging targets and with greater potency …

Proteolysis-targeting chimeric molecules (PROTACs), which attract much more attention
today, may be a potential way to treat cancer. PROTACs are made up of ligands of target …

Small molecule inhibitors of proteins represent important medicines and critical chemical
tools to investigate the biology of the target proteins. Advances in various-omics …

Recently, targeted degradation has emerged as a powerful therapeutic modality. Relying on
“event-driven” pharmacology, proteolysis targeting chimeras (PROTACs) can degrade …